530125-BOM

Samrat Pharmachem Ltd.

BSE: 530125

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

257.50-2.0 (-0.77%)

17 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

Score not available

Value Score

Score not available

Price Momentum Score

Score not available

QVM Score

Score not available

Key Metrics

Market Cap

79.57

P/E (TTM)

P/B

1.17

P/S (TTM)

0.27

EV/EBITDA

CAPE (5Y)

10.00

ROE (TTM)

-4.73

ROCE (TTM)

-3.56

ROA (TTM)

-2.69

Avg 3Y ROE

3.01

Earnings 3Y CAGR

-30.04

Sales 3Y CAGR

-2.30

Sales 5Y CAGR

10.11

Debt/Equity

0.16

Consensus TP

Strong Buy %

Promoter Holding

49.09

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Samrat Pharmachem Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.16 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.02 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 3 financial years

What is Dividend streak?

Negative

Stock is fairly expensive with negative EPS on a trailing 12-month basis

Earnings yield of -4.16% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis

What is Earnings yield (E/P)?

Low and declining ROE

The company reported low ROE of -4.73% for 12-month ended 31 Mar 2026 and ROE declined by -1513 bps from 1 year ago

What is ROE (FY)?

Low and declining operating margin

The company reported low operating margin of -0.99% for 12-month ended 31 Mar 2026 and operating margin declined by -434 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 1.35% for 12-month ended 31 Mar 2026 and the growth was 9.88 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.23

Value 1.35

-82.35114662

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -146.57% for 12-month ended 31 Mar 2026 and the growth was 154.69 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.39%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Samrat Pharmachem Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Samrat Pharmachem Ltd. Shareholding Pattern

Quarterly breakdown of Samrat Pharmachem Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	49.13	49.13	49.13	49.13	49.30	49.30	49.30	49.65	49.65	49.65	49.54	48.64	48.64	48.64	48.64	48.64	48.64	48.64	48.95	49.09	49.09	49.09	49.09	49.09	49.09	49.09
Indian Promoter	49.13	49.13	49.13	49.13	49.30	49.30	49.30	49.65	49.65	49.65	49.54	48.64	48.64	48.64	48.64	48.64	48.64	48.64	48.95	49.09	49.09	49.09	49.09	49.09	49.09	49.09
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	3.24	0.00	3.24	3.24	3.24	3.24	0.00	0.00	3.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Institutions	3.24	0.00	3.24	0.00	0.00	0.00	0.00	3.24	3.24	0.00	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24	3.24
Non-Institution	47.63	47.63	47.63	47.63	47.46	47.46	47.46	47.12	47.12	47.12	47.23	48.13	48.13	48.13	48.13	48.13	48.13	48.13	47.81	47.67	47.67	47.67	47.67	47.67	47.67	47.67
Bodies Corporate	-	2.22	1.91	1.93	1.83	1.90	1.74	2.70	6.02	7.55	7.45	7.76	6.92	6.57	2.67	2.25	3.42	4.27	2.89	2.62	2.59	2.68	2.62	2.67	2.68	2.76
Others (incl. Retail) No. of shareholders	47.63 2,525	45.41 2,577	45.72 2,823	45.70 2,880	45.63 2,859	45.56 5,159	45.72 5,181	44.42 4,808	41.10 4,628	39.57 4,725	39.78 7,340	40.37 7,982	41.21 7,987	41.56 7,879	45.46 8,396	45.88 8,015	44.71 7,426	43.86 7,113	44.92 6,932	45.05 6,795	45.08 6,739	44.99 6,701	45.05 6,650	45.00 6,438	44.99 6,262	44.91 6,279

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

Samrat Pharmachem Ltd. is not part of any tracked index.

Prominent Investor Holdings

Sharad Kanayalal Shah and Associates

Jun 2026

1.13%

₹ 1 Cr

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Samrat Pharmachem Ltd. shares as reported to NSE and BSE.

No bulk, block or insider trade data available.

Corporate Actions

History of Samrat Pharmachem Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 1/share
Record date: 18th Sep 2025Ex-date: 18th Sep 2025
Announced on: 30th May 2025
Dividend₹ 1/share
Record date: 19th Sep 2024Ex-date: 19th Sep 2024
Announced on: 30th May 2024
Dividend₹ 1/share
Record date: 18th Sep 2023Ex-date: 18th Sep 2023
Announced on: 30th May 2023
Dividend₹ 1/share
Record date: 22nd Sep 2022Ex-date: 22nd Sep 2022
Announced on: 2nd Sep 2022

Company Profile

Overview of Samrat Pharmachem Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Samrat Pharmachem Limited is an India-based manufacturer of iodine salts. The Company is engaged in the business of pharmaceutical chemicals. Its products include 3-5 Di Iodosalicylic Acid, Ammonium Iodide, Cadmium Iodide, Calcium Iodate, Clioquinol, Copper Iodide, Ethyl Iodide, Ethylenediamine Dihy...

Key personnel

Mr. Nishant Kumar Kankaria

Compliance Officer, Company Secretary

Mr. Lalit Damodar MehtaD

Executive Chairman of the Board, Managing Director

Mr. Megh Rajesh MehtaD

Executive Director

Mr. Rajesh Lalit MehtaD

Executive Director

Mr. Piyush Gangji DharodD

Additional Non-Executive Independent Director

Ms. Megha JainD

Non-Executive Independent Director

Mr. Sachin KotharyD

Non-Executive Independent Director

Mr. Manishkumar PipaliaD

Non-Executive Independent Director

Incorporated on

16 Jun 1992

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

28 Feb 1995

Free Float

12,58,732

Website

https://www.samratpharmachem.com/

Phone no.

+917045456789

Address

701/702, Business Square, M. A. Road, Andheri (West), MUMBAI, 400058, India

Frequently Asked Questions

What is the current share price of Samrat Pharmachem Ltd.?

The current share price of Samrat Pharmachem Ltd. is ₹ 257.50 as of 17 Jul 2026.

What is the market capitalisation of Samrat Pharmachem Ltd.?

The market capitalisation of Samrat Pharmachem Ltd. stands at ₹ 79.57 Cr.

What is the PE ratio of Samrat Pharmachem Ltd.?

The Price-to-Earnings (PE) ratio of Samrat Pharmachem Ltd. is - as of the latest trailing twelve months data.

What is the ROE and ROCE of Samrat Pharmachem Ltd.?

Samrat Pharmachem Ltd. has a Return on Equity (ROE) of -4.73% and a Return on Capital Employed (ROCE) of -3.56% as per the latest financial reports.

What is the 52-week high and low of Samrat Pharmachem Ltd.?

The 52-week high of Samrat Pharmachem Ltd. is - and the 52-week low is -.

What is the dividend yield of Samrat Pharmachem Ltd.?

The dividend yield of Samrat Pharmachem Ltd. is 0.39% based on the current market price.

What is the FII and DII holding in Samrat Pharmachem Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 44.91% of Samrat Pharmachem Ltd. shares.

What sector does Samrat Pharmachem Ltd. belong to?

Samrat Pharmachem Ltd. operates in the Healthcare sector.

What is the beta of Samrat Pharmachem Ltd.?

The beta of Samrat Pharmachem Ltd. is 0.77, indicating its price volatility relative to the broader market. Over the past 1 year, Samrat Pharmachem Ltd. has delivered an absolute return of -31.90%.

What is the RSI of Samrat Pharmachem Ltd.?

The 14-day Relative Strength Index (RSI) of Samrat Pharmachem Ltd. is 60.33, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Samrat Pharmachem Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Samrat Pharmachem Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Holdings and Presence

Corporate Actions